Sitting on Gold: Why Universities Consistently Fail to Monetise the Knowledge They Create

In 2020, the mRNA technology underlying the Covid-19 vaccines that would eventually reach billions of people was traced in part to foundational patents held by the University of Pennsylvania. The institution received a significant share of royalties — a rare and celebrated outcome. What received less attention was the prior decade: years during which the university's technology transfer office had struggled to find licensees for the technology, during which its inventors had faced scepticism from pharmaceutical partners, and during which the patents had come perilously close to being abandoned entirely. The story of university knowledge monetisation is less often a story of triumph than of near-misses, abandoned assets, and value that quietly leaves the building.

That mRNA story is exceptional precisely because it had an ending. Most university-generated intellectual property does not. Understanding why — and who bears the cost — requires examining how research institutions came to hold enormous knowledge assets they have never been structurally equipped to exploit.

The architecture of the problem begins, again, with Bayh-Dole. When the 1980 US legislation transferred IP ownership from the federal government to universities, it created an institutional obligation without a commensurate institutional capability. Universities suddenly owned patents. They did not suddenly know how to value, position, market, or licence them — nor did they have the commercial networks, the deal-making culture, or the risk tolerance that effective technology commercialisation requires.

European universities followed a similar trajectory through the 1990s and 2000s as national governments, inspired partly by the Bayh-Dole model, passed legislation assigning IP rights to institutions rather than individual inventors. In Germany, the so-called Professor's Privilege — under which academics had historically owned their own inventions — was abolished in 2002, transferring ownership to universities. Similar reforms followed in Austria, Denmark, and Norway. The institutional portfolio of university-held IP expanded dramatically. The institutional capacity to do anything useful with it expanded far more slowly.

The deeper structural issue is one of mission conflict. Universities are constituted to educate, to conduct research, and to disseminate knowledge freely. Monetisation requires the opposite of free dissemination: it requires controlling access, timing disclosures strategically, and negotiating from positions of commercial self-interest. These imperatives sit in genuine tension with open science norms, and most universities have never resolved that tension — they have simply added a commercialisation mandate on top of an academic culture that was not built to accommodate it.

The financial consequences for universities are substantial but abstract — foregone revenues that never appear on a balance sheet. The consequences for individual researchers are concrete and immediate. A scientist whose work generates a patent that the institution holds, never licences, and eventually allows to lapse has lost not only the commercial opportunity but the five to ten years of development time that preceded it. She typically receives no explanation, no alternative pathway, and no acknowledgement that the institution's failure to act is distinct from the work's lack of value.

The human dimension of this failure is often framed in purely financial terms, but the damage runs deeper. Researchers who see their work disappear into an institutional IP portfolio — held, unmarketed, and eventually expired — face a specific kind of professional disillusionment that is difficult to recover from. They entered science partly because they believed their work could matter beyond the laboratory. The discovery that the institution formally responsible for translating that work to impact is structurally incapable of doing so is not a minor administrative disappointment. It is a rupture in the foundational logic of an academic career.

There is also a subtler dynamic involving IP control that shapes researchers' behaviour long before any patent expires. Many scientists are deeply, rationally fearful of losing control of their work through the commercialisation process. They have heard stories — and there are many — of licensing agreements that assigned commercial rights so broadly that the researcher could no longer use their own methods, of industry partnerships that redirected research agendas toward near-term product goals and away from the foundational questions the researcher cared about, of spinout equity structures that left the inventor as a minority stakeholder in something they built.

This fear is not irrational. University commercialisation agreements have historically favoured institutional IP capture over inventor interests, and the negotiating asymmetry between a junior researcher and an institution's legal team is significant. The result is a population of scientists sitting on commercially valuable work they are reluctant to release into a system they do not trust — and an institution sitting on an unrealised portfolio it does not have the capability to develop.

What the gap requires is not another internal process reform, nor a more aggressive licensing push from a TTO that already lacks the resources to handle its existing caseload. It is something the university system has never reliably provided: a bridge between the laboratory and the investor that the researcher can trust to act in their interest, not merely the institution's.

The most effective commercialisation outcomes in university research tend to share a common feature: a trusted intermediary who understands the science, can represent it credibly to commercial and investment audiences, and is structurally positioned to protect the researcher's interest throughout the process. Not a lawyer whose primary obligation is to the institution. Not a TTO officer managing eighty cases simultaneously. But a dedicated partner whose role is to move the work from laboratory to investment-ready opportunity without the researcher surrendering the thing they most need to protect — control over what they built and how it enters the world.

This means preparing the materials that allow investors to evaluate the opportunity honestly: the technical landscape, the market sizing, the IP position clearly articulated, the development roadmap. It means structuring the conversation with potential partners before it becomes a negotiation — so that the researcher enters any deal process informed, represented, and in a position to say no as well as yes. And it means doing this in a way that works alongside the university's existing machinery rather than triggering the institutional defensiveness that tends to slow everything down.

The knowledge sitting in university laboratories across Europe and North America is not lacking in value. What it consistently lacks is a pathway to realise that value that the people who created it can actually trust. That missing bridge — from laboratory to investor, without loss of control — is not a technological problem or a legal one. It is a relationship problem, and it has a human solution.